The study is a 6 month, placebo-controlled study of transdermal testosterone for women with HIV-associated weight loss. Women with AIDS wasting have been found to have low testosterone levels. This study is designed to test the efficacy of physiologic testosterone dosing to improve weight, muscle mass and quality of life indices, including energy level, appetite and libido, in androgen deficient women with AIDS wasting. After 6 months, all women receive open label transdermal testosterone for an additional 6 months.

Androgen, estrogen, progestational derivative, or glucocorticoid administration within 3 months of the study, including Megace

New retroviral therapy within 6 weeks of study

SGOT > 5 X normal and/or clinically significant liver disease

Creatinine > 2.0 mg/dL and/or clinically significant renal disease

Hgb < 8.0 g/dL

Active substance abuse or alcoholism

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00006158